Erasca Inc ERAS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ERAS is a good fit for your portfolio.
News
-
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
-
Erasca Announces $45 Million Oversubscribed Private Placement Financing
-
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
-
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
-
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Erasca's Eras-801 for Treatment of Brain Tumors Gets FDA Orphan Drug Designation
Trading Information
- Previous Close Price
- $1.88
- Day Range
- $1.84–1.91
- 52-Week Range
- $1.51–3.38
- Bid/Ask
- $1.88 / $1.95
- Market Cap
- $286.32 Mil
- Volume/Avg
- 255,612 / 808,215
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 129
- Website
- https://www.erasca.com
Comparables
Valuation
|
Metric
|
ERAS
|
BMEA
|
ARVN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.88 | 2.28 | 3.26 |
Price/Sales | — | — | 22.34 |
Price/Cash Flow | — | — | — |
Price/Earnings
ERAS
BMEA
ARVN
Financial Strength
|
Metric
|
ERAS
|
BMEA
|
ARVN
|
|---|---|---|---|
Quick Ratio | 11.94 | 7.74 | 4.93 |
Current Ratio | 12.26 | 7.84 | 4.98 |
Interest Coverage | — | — | — |
Quick Ratio
ERAS
BMEA
ARVN
Profitability
|
Metric
|
ERAS
|
BMEA
|
ARVN
|
|---|---|---|---|
Return on Assets (Normalized) | −22.08% | −56.31% | −26.31% |
Return on Equity (Normalized) | −27.20% | −65.70% | −58.35% |
Return on Invested Capital (Normalized) | −27.50% | −67.02% | −63.59% |
Return on Assets
ERAS
BMEA
ARVN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hynlpkncjz | Clc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xsqtwcmyf | Jsrdnq | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wkyxystm | Llhsbnt | $97.8 Bil | |
MRNA
| Moderna Inc | Kwqynnbb | Sqs | $41.3 Bil | |
ARGX
| argenx SE ADR | Zvqsqtwt | Dzrvj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Xqhtqbsbc | Kmh | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Knwwkzsh | Kctpj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vgbpdlgrh | Hdbfbh | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ynzkjpwp | Kbqzmzx | $12.5 Bil | |
INCY
| Incyte Corp | Yhtpmgd | Zqjqrpp | $11.6 Bil |